SHR-1701 in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
Condition: Nasopharyngeal Carcinoma Intervention: Drug: SHR-1701 Sponsor: Jiangsu HengRui Medicine Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials